Comparing 2 hypotheses side-by-side
Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.
Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | RNA-Binding Competition Therap | Transglutaminase-2 Cross-Linki |
|---|---|---|
| Mechanistic | 0.500 | 0.750 |
| Evidence | 0.400 | 0.600 |
| Novelty | 0.850 | 0.700 |
| Feasibility | 0.250 | 0.800 |
| Impact | 0.450 | 0.700 |
| Druggability | 0.300 | 0.850 |
| Safety | 0.250 | 0.650 |
| Competition | 0.750 | 0.750 |
| Data | 0.350 | 0.700 |
| Reproducible | 0.300 | 0.750 |
| KG Connect | 0.788 | 0.742 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["TDP-43 / TARDBP"] --> B["RNA Processing Functions"]
B --> C["Splicing Regulation"]
B --> D["RNA Transport"]
B --> E["RNA Stability"]
F["Pathological Conditions"] --> G["Cytoplasmic Mislocalization"]
G --> H["Hyperphosphorylation"]
H --> I["TDP-43 Aggregation"]
I --> J["Cross-Seeding with Other Proteins"]
J --> K["ALS/FTD Pathology"]
L["RNA-Binding Competition Therapy"] --> M["Designed RNA Decoys"]
M --> N["Compete for TDP-43 RNA-Binding Domain"]
N --> O["Sequester TDP-43 in Soluble Form"]
O --> P["Prevent Cytoplasmic Aggregation"]
O --> Q["Block Cross-Seeding"]
O --> R["Preserve Some RNA Processing"]
P --> S["Reduced TDP-43 Inclusions"]
Q --> T["Prevented Prion-like Spread"]
R --> U["Maintained Cellular Function"]
S --> V["Neuroprotection in ALS/FTD"]
T --> V
U --> V
style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
style F fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
style L fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
graph TD
A["""Neuroinflammation
& Calcium Dysregulation"""] -->|"Ca2+ Influx"| B["TG2 Activation
(Transglutaminase-2)"]
B -->|"Isopeptide Bond
Formation"| C["Tau Cross-Linking
& Aggregation"]
B -->|"Protein Cross-Linking"| D["Abeta Oligomer
Stabilization"]
B -->|"ECM Cross-Linking"| E["BBB Disruption
& Matrix Stiffening"]
B -->|"NF-kappaB Activation"| F["Pro-inflammatory
Cytokine Cascade"]
C --> G["Neurofibrillary
Tangle Formation"]
D --> H["Amyloid Plaque
Stabilization"]
E --> I["Peripheral Immune
Cell Infiltration"]
F --> J["Chronic
Neuroinflammation"]
G --> K["Neuronal Death
& Cognitive Decline"]
H --> K
I --> J
J --> K
L["""TG2 Inhibitor
Therapy"""] -->|"Selective Active-Site
Blockade"| M["TG2 Cross-Linking
Inhibition"]
M -->|"Reduced Tau
Cross-Linking"| N["Prevented Tangle
Formation"]
M -->|"Reduced Abeta
Stabilization"| O["Enhanced Abeta
Clearance"]
M -->|"Preserved BBB
Integrity"| P["Reduced Immune
Infiltration"]
M -->|"Suppressed NF-kappaB"| Q["Reduced
Neuroinflammation"]
N --> R["Neuroprotection &
Cognitive Preservation"]
O --> R
P --> R
Q --> R
style A fill:#ff8a80,stroke:#d32f2f,color:#000
style L fill:#4fc3f7,stroke:#2196f3,color:#000
style R fill:#81c784,stroke:#4caf50,color:#000
style K fill:#ffab91,stroke:#e64a19,color:#000